Expansion of the Emerging-Markets Business with India as a Key Market
First written in FY2024. 2 of 4 entries say "Advanced", first in FY2025-H1. Latest entry: FY2026.
1 other company's latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「In India, a new production facility equipped with the Group’s first production capabilities for both diagnostic reagents and instruments, developed in response to the Make in India policy and other initiatives, has entered full-scale operation, with local production now under way. In China and India, we are also promoting the local procurement of raw materials in each country and working to strengthen the Group’s supply capacity.」
The policy of treating India as a key market has progressed to full-scale operation and local production at the new facility, as well as local raw-material procurement in China and India. - FY2026-H1Disclosure of depreciation expense impact from the new production facility in IndiaAnnual report
「In terms of profit, although revenue increased, the cost of sales ratio deteriorated due to depreciation and other expenses related to the new production facility in India, which was completed in August 2024. Segment profit (operating profit) was ¥3,626 million, down 3.1% year on year.」
Depreciation and other expenses following the completion of the new production facility in India emerged in the results as factors behind the deterioration in the cost of sales ratio and the decline in segment profit for the AP segment. - FY2025-H1AdvancedAnnual report
「Against this backdrop, the Company completed construction in India of a new production facility with the Group's first production capabilities for both reagents and instruments. This new facility has the largest total floor area among the Group's overseas production sites, will substantially expand the range of reagents produced, and has production capabilities for instruments in response to the Make in India policy. Through these measures, the Company aims to strengthen its supply capacity to meet strong demand for testing and accelerate and sustain the growth of its business in India.」
With India positioned as a key market, construction has been completed on a new facility with production capabilities for both reagents and instruments, giving concrete form to efforts to strengthen supply capacity and accelerate business expansion. Shipments of both reagent and instrument products are planned to begin during the fiscal year ending March 2025. - FY2024First statedAnnual report
「In particular, we position India as a key market, accelerate business planning, product development and market entry, and work to expand market share in emerging markets.」
For the first time, explicitly stated the policy of positioning India as a key market among priority initiatives for emerging markets and accelerating business planning, product development and market entry.